RHOT1 and Parkinson disease: Remarkably, compound‐3 displayed the ability to lower Miro1 levels post‐mitochondrial depolarization, providing neuroprotection in patient‐derived PD fibroblasts and Drosophila models, marking a significant advancement in therapeutic strategies [108].